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 ABSTRACT
Myeloma-associated renal disorders are rare events among renal transplants and can occur as recurrent or 
de novo disease. We describe an unusual case of renal allograft dysfunction due to myeloma cast nephropathy 
occurring 19 years after having received a renal transplant in a patient with no prior history of multiple myeloma 
or monoclonal gammopathy preceding transplantation. Our patient was treated with five cycles of chemother-
aphy (bortezomib, melphalan and steroids), which resulted in short-term improvement in allograft dysfunction 
and complete haematological remission. The longer patient and graft survival after renal transplantation make 
post-transplant lymphoproliferative disease more frequent. Multiple myeloma after kidney transplant is rare and 
an elevated index of suspicion is necessary to make a timely diagnosis of this serious disease. Further work is 
needed to identify the best treatment options for these patients.
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 INTRODUCTION
Kidney transplantation has experienced dramatic 
developments over the years, in the treatment and is 
now the standard treatment for patients with end-stage 
renal disease1.
An increased incidence of neoplasm in transplant 
recipients was first recognized in the 1970s as a serious 
complication2. With longer graft survival and older 
donors (as well as recipients) and with the introduction 
of more potent immunosuppressive medication, cancers 
complicating organ allograft are a major cause of mor-
bidity and mortality after renal transplantation2,3.
In published studies, the incidence of cancer in 
renal transplant recipients ranges from 2.3-31%3,4. 
Of these, post-transplant lymphoproliferative disease 
(PTLD) is a serious complication of solid organ trans-
plantation, with an increased risk compared to both 
the general population and patients on transplant 
waiting lists5,6.
Factors predisposing to this increased risk of malig-
nancy include impaired immune surveillance due to 
use of high-dose immunosuppressive drugs; primary 
infection or recrudescence of viral infections, such as 
Epstein-Barr virus, Herpes virus and hepatitis C virus 
(HCV), and older age5,7-9.
In the United States, approximately around 1% of 
all cancers and 10% of haematological malignancies in 
the general population are due to multiple myelo-
ma10,11. However, despite the frequency of multiple 
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myeloma, there is limited experience with multiple 
myeloma in renal transplantation11.
Myeloma-associated kidney disorders occur as recur-
rent disease, and rarely de novo in kidney transplant 
recipients11,12. These kidney disorders usually manifest 
with worsening allograft function and proteinuria13. 
Little is known about the course and outcome of 
patients who develop multiple myeloma after kidney 
transplantation. In the first published cases7,13-15 the 
outcome was poor because the therapeutic regimen 
with alkylator-based therapy used in an immunosup-
pressed population often resulted in severe infection 
and death. We believe that this scenario is now quite 
different with the advent of new myeloma therapies 
and with the use of less aggressive immunosuppressive 
protocols.
We report the case of one patient who developed 
multiple myeloma 19 years after having received a renal 
transplant.
 CASE REPORT
A 51-year-old Caucasian female with an autosomal 
dominant polycystic kidney disease was transplanted 
with a deceased allograft kidney in 1993. Her past medi-
cal history was significant for hypertension and HCV. 
There was no clinical evidence of multiple myeloma at 
that time. There were four HLA mismatches (A, B and 
DR). The surgical procedure was uneventful and immu-
nosuppression (ISS) consisted of prednisolone, cyclo-
sporine and azathioprine. The optimal plasma creati-
nine after transplantation was 1.0 mg/dl and the patient 
was diagnosed at discharge with new onset diabetes 
after transplantation.
In the first two years after transplantation patient 
experienced cytomegalovirus infection, treated with 
ganciclovir, and several Escherichia coli urinary tract 
infections (UTI). In the third year post-transplantation, 
renal function declined to a plasma creatinine 1.5 mg/
dl. An allograft biopsy was made at this point and 
showed interstitial fibrosis and tubular atrophy and 
arteriolar hyaline thickening, suggesting calcineurin 
inhibitor toxicity. The cyclosporine dose was reduced. 
In the fifth year after transplantation, azathioprine was 
switched to mycophenolate mofetil.
At 7th year post-transplantation the patient was 
diagnosed with vesicoureteral reflux into the 
transplanted kidney during investigation of underlying 
causes of recurrent UTI. She was treated by endoscopic 
subureteral collagen injection.
Nine years after transplantation she started eryth-
ropoiesis-stimulating agents (ESA) to achieve normo-
chromic normocytic anaemia control (darbepoetin alfa 
20 mcg, biweekly). In the thirteenth year after trans-
plantation, cyclosporine was switched to tacrolimus as 
cyclosporine-related minor side effects were observed.
Over the next few years, follow-up visits in the trans-
plant clinic were unremarkable except for several UTI 
and an increase in ESA dose (from 20 to 80 mcg, week-
ly). to correct anaemia. The allograft function remained 
stable (Scr 1.3 mg/dl).
At the follow-up visit during the 19th year post-
transplant the patient presented with asthenia and 
fatigue at minimal efforts. At the time her ISS consisted 
of tacrolimus (1.5 mg/day) and mycophenolate mofetil 
(750 mg/day). Mild graft dysfunction was present with 
a slight creatinine increase (from 1.4 to 1.9 mg/dl). 
Laboratory work-up revealed haemoglobin of 11 g/dl, 
total leukocyte count of 5800/mm3 and a normal dif-
ferential count. Serum albumin was 3.6 g/dl, serum 
calcium 9.2 mg/dl, phosphorus 5.8 mg/dl and alkaline 
phosphatase 73 U/L. Serum protein electrophoresis 
revealed the presence of de novo M band and urinary 
Bence Jones proteins were positive. Serum immuno-
electrophoresis showed immunoglobulin A (IgA) lamb-
da monoclonal gammopathy of 1819 mg/dL and pres-
ence of urine protein electrophoresis was positive for 
an abnormal lambda monoclonal band.
An allograft kidney biopsy was performed due to 
mild creatinine increase and IgA lambda gammopathy. 
The optical microscopy revealed normal glomeruli and 
vessels. The majority of proximal tubules were normal. 
The more profound cortical and the medullar region 
presented interstitial fibrosis, with mild mononuclear 
cells infiltrates and tubular atrophy with polymorphic, 
dense and fragmented tubular casts. One tubular cast 
was involved by a multinucleated giant cell (Figure 1). 
The immunofluorescence, performed in frozen frag-
ment, was only positive to immunoglobulin lambda 
light chain in tubular casts (Figure 2). The Congo Red 
coloration was negative. Lambda cast nephropathy was 
the final histological diagnosis.
Subsequent bone marrow showed 30% mature and 
immature plasma cells, confirming the diagnosis of 
myeloma. Skeletal survey revealed one osteolytic 
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lesion in the skull. The patient was referred to hae-
matology and started 5 weekly cycles of chemother-
apy. Each cycle consisted of 4 days of bortezomib (1.3 
mg/m2 daily), 4 days of melphalan (9 ml/m2 daily) 
and 4 days of oral dexamethasone (40 mg daily). She 
received a total of 5 cycles of chemotherapy, resulting 
in a complete haematological remission represented 
by normal IgA lambda levels, negative immunofixation 
and recovery of baseline graft function. During chemo-
therapy, she developed leukopaenia and mycopheno-
late mofetil was withdrawn, maintaining tacrolimus 
monotherapy.
The patient continued to be followed-up at the hae-
matology and transplant clinic, with monitoring of 
immunoelectrophoresis and free light chain.
Five months after the last treatment, tacrolimus was 
switched to everolimus. This caused proteinuria wors-
ening which led to everolimus suspension and tacroli-
mus re-introduction.
Eighteen months after last chemotherapy cycle she 
remains in complete haematological remission with a 
stable kidney function and serum creatinine level sus-
tained at 1.3 mg/dL.
Her current immunosuppression consists of tacroli-
mus and mycophenolate mofetil.
Presently, she is 74 years old, 21 years after kidney 
transplantation and remains in complete haematologi-
cal remission with stable allograft function.
 DISCUSSION
PTLD are well-known complication after renal trans-
plantation and occur more frequently in situations 
where an aggressive immunosuppressive protocol has 
been used. In PTLP spectrum, patients with malignant 
lymphomas/multiple myeloma are older, develop the 
lesions after a longer time interval after transplanta-
tion18, have a higher stage of disease at presentation 
and lower probability of response to implemented 
therapeutic strategies8.
Myeloma-associated kidney disorders have been 
reported with diverse clinical and histological manifesta-
tions in solid organ transplant recipients15,19. This entity 
usually occurs as recurrent disease, and rarely de novo 
in kidney transplant recipients. The risk of developing 
de novo myeloma after renal transplantation is 4.4 times 
higher than in the general population; however, this 
accounts for only 1.3% of all malignancies over a period 
exceeding 25 years, per the ANZDATA report8,20.
It is possible that in some cases a previous unde-
tected monoclonal gammopathy of undetermined 
significance (MGUS), preexisting prior to transplanta-
tion, could evolve into manifest myeloma post-trans-
plant as a result of the immunosuppressive regimen. 
In cases of known and treated myeloma, the disease 
could recur despite achieving successful remission 
prior to transplantation15.
Figure 1
Masson Trichrome, X400- Giant cell involving cast in a distal tubule.
 
Figure 2
Immunofluorescence of frozen fragment, X500: Lambda immunoglob-
ulin light chain positive in tubular cast.
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Presence of monoclonal or oligoclonal gammopa-
thies is, however, not infrequent after transplantation. 
Incidence of benign gammopathies after transplanta-
tion varies between 10-30%7. Post-transplant MGUS is 
often transient, usually associated with intense immu-
nosuppression, and the amount of M protein is usually 
small, and it may have multiple bands11,21.
Light chains (LCs) are removed from the circulation 
by the kidney. Filtered LCs are reabsorbed by proximal 
tubule epithelial cells via receptor-mediated endocy-
tosis via the tandem endocytic receptors megalin/
cubilin22. Excessive endocytosis of LCs triggers activa-
tion of nuclear factor jB, which in turn promotes 
cytokine and chemokine expression leading to tubu-
lointerstitial fibrosis and scarring24.
The potential precipitants for myeloma cast nephrop-
athy in post-transplant patients include calcineurin 
inhibitor toxicity, prolonged cold ischaemia time, tran-
sient hypovolaemia, and sudden exposure of the 
allograft to a high load of filtered free monoclonal light 
chains23.
Although kappa LCs are more commonly reported, 
there are few cases11,15 reporting lambda LC involve-
ment in a renal allograft. It is not known if these patho-
logical differences have significance in clinical outcome 
and allograft survival.
Renal insufficiency is common in multiple myeloma 
and is present in almost 50% of patients at the time of 
diagnosis. There is a negative correlation between the 
presence and severity of renal disease and patient 
survival25.
The response of the renal disease to therapy also 
appears to have prognostic value24,26. The proteasomal 
inhibitor bortezomib has represented a significant 
therapeutic step forward in the treatment of multiple 
myeloma since its approval in 2003. Bortezomib is asso-
ciated with significant improvements in response rates, 
complete remission rates, event-free survival, patient 
survival and renal recovery rates24,27. Other chemo-
therapeutic agents with increasing use in patients 
include thalidomide and lenalidomide, presenting simi-
lar results to bortezomib26.
The role for therapeutic plasma exchange (TPE) in 
treatment of myeloma cast nephropathy remains con-
troversial with contrasting results from different stud-
ies28-30, although the largest randomized controlled 
trial of TPE did not demonstrate any benefit30. Extended 
daily high cut-off haemodialysis (HCO-HD) has also been 
shown to allow removal of large amounts of serum 
free light chains31. Nevertheless, the studies only report 
reduction in free LC concentrations with HCO-HD in 
combination with chemotherapy. Currently is not 
known whether HCO-HD offers any additional benefit 
over current chemotherapeutic regimens. Randomized 
trials are in progress in this regard31.
There are no definite treatment protocols for patients 
with multiple myeloma who are eligible for kidney 
transplantation. Kuypers et al.32 have reported a case 
in which rituximab, an anti CD20 monoclonal antibody, 
delayed the recurrence of LC nephropathy in the allo-
graft kidney. Some authors believe that dose-intensive 
chemotherapy / high dose intensity of chemotherapy 
followed by stem cell transplantation could decrease 
disease recurrence in the allograft kidney33.
The reported cases of myeloma-associated renal 
disorders in the transplant population are rare, with 
less than 50 reported. The described cases presenta-
tions were primary allograft dysfunction13,14,16,17,24 
or renal impairment several months or years after renal 
transplantation7,11,15. In both presentations forms, 
allograft survival is poor. In 2011, Goel et al.24 published 
the first recovery of graft function. The patient had an 
established diagnosis of primary allograft dysfunction 
due to allograft myeloma cast nephropathy and had 
been treated with plasmapheresis, chemotheraphy 
using bortezomib and dexamethasone. Before that, 
Solak et al.34 reported a haematological remission with-
out graft recovery in a patient with post-transplant 
myeloma treated with bortezomib.
The largest series, of seven patients with multiple 
myeloma after undergoing kidney transplantation, was 
recently published11. The authors showed that there 
is significant renal involvement in these patients and 
patient and renal allograft survival were not worse than 
those of the general population with multiple myeloma 
and kidney transplantation, respectively. However, the 
authors call attention to the fact that these results 
should be interpreted with caution because of the small 
sample size and that those patients who receive kidney 
transplantation are highly selected, which probably 
introduces bias11.
Our case illustrates the rare occurrence of multiple 
myeloma IgA lambda in a renal transplant recipient. 
The presence of lambda LC in casts is uncommon since 
most published cases showed involvement of kappa 
LC. This is the first case of post-transplant de novo 
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multiple myeloma seen in 1180 renal transplant patients 
followed up at our center.
The patient has responded to the implemented treat-
ment of triple chemotherapy with dexamethasone, 
melphalan and bortezomib. Despite her advanced age 
and prolonged graft survival, treatment response was 
excellent. She achieved sustained complete haemato-
logical remission and returned to her basal allograft 
function. There were no complications associated with 
chemotherapy. This case is a strong argument that 
bortezomib could contribute to changing these patients’ 
outcomes.
An elevated index of suspicion is necessary to make 
a timely diagnosis of this serious disease, which prob-
ably determines a better prognosis24. Anaemia and 
increased need for ESA were the early signs of disease. 
This case also raises the question of the routine use of 
protein serum electrophoresis as part of the post-
transplant evaluation. Working together with Haema-
tology was also critical to the success achieved.
In conclusion, although there are only a few cases 
described in the literature of this entity, we should not 
forget its existence, so we promote a rapid therapeutic 
intervention. In the last years, advances in treatment 
have led to an improvement of renal and vital 
prognosis.
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